148 related articles for article (PubMed ID: 30254184)
1. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.
Handle F; Puhr M; Schaefer G; Lorito N; Hoefer J; Gruber M; Guggenberger F; Santer FR; Marques RB; van Weerden WM; Claessens F; Erb HHH; Culig Z
Mol Cancer Ther; 2018 Dec; 17(12):2722-2731. PubMed ID: 30254184
[TBL] [Abstract][Full Text] [Related]
2. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
Hellsten R; Lilljebjörn L; Johansson M; Leandersson K; Bjartell A
Prostate; 2019 Oct; 79(14):1611-1621. PubMed ID: 31348843
[TBL] [Abstract][Full Text] [Related]
3. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A
Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788
[TBL] [Abstract][Full Text] [Related]
4. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
[TBL] [Abstract][Full Text] [Related]
5. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
6. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.
Don-Doncow N; Escobar Z; Johansson M; Kjellström S; Garcia V; Munoz E; Sterner O; Bjartell A; Hellsten R
J Biol Chem; 2014 Jun; 289(23):15969-78. PubMed ID: 24755219
[TBL] [Abstract][Full Text] [Related]
7. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
[TBL] [Abstract][Full Text] [Related]
8. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Liu C; Lou W; Armstrong C; Zhu Y; Evans CP; Gao AC
Prostate; 2015 Sep; 75(13):1341-53. PubMed ID: 25970160
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.
Hsu FN; Chen MC; Lin KC; Peng YT; Li PC; Lin E; Chiang MC; Hsieh JT; Lin H
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E975-86. PubMed ID: 23941877
[TBL] [Abstract][Full Text] [Related]
11. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells.
Hellsten R; Johansson M; Dahlman A; Sterner O; Bjartell A
PLoS One; 2011; 6(7):e22118. PubMed ID: 21779382
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
13. 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.
Dambal S; Alfaqih M; Sanders S; Maravilla E; Ramirez-Torres A; Galvan GC; Reis-Sobreiro M; Rotinen M; Driver LM; Behrove MS; Talisman TJ; Yoon J; You S; Turkson J; Chi JT; Freeman MR; Macias E; Freedland SJ
Mol Cancer Res; 2020 May; 18(5):671-684. PubMed ID: 32019810
[TBL] [Abstract][Full Text] [Related]
14. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
16. STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population.
Canesin G; Maggio V; Palominos M; Stiehm A; Contreras HR; Castellón EA; Morote J; Paciucci R; Maitland NJ; Bjartell A; Hellsten R
Sci Rep; 2020 Aug; 10(1):13958. PubMed ID: 32811873
[TBL] [Abstract][Full Text] [Related]
17. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
18. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
Andersen RJ; Mawji NR; Wang J; Wang G; Haile S; Myung JK; Watt K; Tam T; Yang YC; Bañuelos CA; Williams DE; McEwan IJ; Wang Y; Sadar MD
Cancer Cell; 2010 Jun; 17(6):535-46. PubMed ID: 20541699
[TBL] [Abstract][Full Text] [Related]
19. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
20. SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.
Handle F; Erb HH; Luef B; Hoefer J; Dietrich D; Parson W; Kristiansen G; Santer FR; Culig Z
Mol Cancer Res; 2016 Jun; 14(6):574-85. PubMed ID: 27053681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
